41 results on '"CONSALVI, SARA"'
Search Results
2. Contributors
3. Biological Activities of Synthetic Derivatives of Xanthones: An Update (2016-2020)
4. Amino Acid Biosynthesis Inhibitors in Tuberculosis Drug Discovery
5. 6-Fluorophenylbenzohydrazides inhibit Mycobacterium tuberculosis growth through alteration of tryptophan biosynthesis
6. Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy
7. Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis
8. SAR Analysis of Novel Coxsackie virus A9 Capsid Binders.
9. Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?
10. Transmission-Blocking Strategies for Malaria Eradication: Recent Advances in Small-Molecule Drug Development.
11. In vivo potent BM635 analogue with improved drug-like properties
12. Pharmaceutical salt of BM635 with improved bioavailability
13. Development of MmpL3 inhibitors for tuberculosis treatment
14. Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9
15. Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors
16. 1,5-Diarylpyrroles as potent antitubercular and anti-inflammatory agents
17. Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances
18. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development
19. Chapter 3 - Therapeutic potential for coxib-nitric oxide releasing hybrids in cancer treatment
20. Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors
21. A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity
22. Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme
23. Malaria transmission blocking compounds: a patent review
24. Nano-Based Drug Delivery Systems of Potent MmpL3 Inhibitors for Tuberculosis Treatment
25. A Novel Class of Dual-Acting DCH-CORMs Counteracts Oxidative Stress-Induced Inflammation in Human Primary Tenocytes
26. Overcoming drug resistance in TB: an update
27. SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis
28. Synthesis and biological evaluation of 1,5-diphenylpyrrole derivatives as COX-2 selective inhibitors and NO-releasing agents and development of a novel BRD9 chemical probe
29. Chapter Three - Development of MmpL3 inhibitors for tuberculosis treatment
30. Chocolate Consumers and Lymphocyte-to-Monocyte Ratio: A Working Hypothesis from a Preliminary Report of a Pilot Study in Celiac Subjects
31. Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis
32. HDAC4 regulates satellite cell proliferation and differentiation by targeting P21 and Sharp1 genes
33. Novel inhibitors of Mycobacterium tuberculosis tryptophan biosynthetic pathway to treat tuberculosis
34. MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target
35. A Series of COX-2 Inhibitors Endowed with NO-Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis
36. Improving the solubility and the biological profile of a novel class of derivatives as selective COX-2 inhibiting nitric oxide donors
37. Development of a novel class of derivatives as selective COX-2 inhibiting Nitric Oxide donors: improving the solubility and the biological profile
38. New 1,5-diphenyl pyrrole derivatives as anti-inflammatory COX-2 selective compounds and their use as potential antitumoral agents
39. New Pyrrole Derivatives as Anti-inflammatory and Analgesic Agents: Design, Synthesis and Biological Evaluation
40. COX inhibitors: a patent review (2011 – 2014)
41. MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.